US biotech firm Alzheon has announced the publication of clinical results demonstrating that ALZ-801 achieved levels of therapeutic efficacy with favorable safety and tolerability profile for use as an orally-administered medicine for the treatment of Alzheimer’s disease. 25 October 2017
US biopharma major AbbVie and portfolio company Alector, a privately owned biotech, today announced a global strategic collaboration to develop and commercialize medicines to treat Alzheimer’s disease and other neurodegenerative disorders. 24 October 2017
Switzerland-based Idorsia today announced its financial results and an update on its research progress, which represent the business activity in the three and a half months since the demerger from Actelion on June 15, 2017, following the $30 billion acquisition by Johnson & Johnson. 24 October 2017
Japanese and US pharma majors Eisai and Biogen say they have expanded their existing agreement to jointly develop and commercialize investigational Alzheimer’s disease treatments. 23 October 2017
US President Donald Trump on Tuesday said his nominee to head the Office of National Drug Control Policy, Representative Tom Marino (Republican, Pennsylvania.), has backed out of the position, two days after media reports revealed the congressman had pushed legislation gutting the US Drug Enforcement Administration's ability to target opioid distributors not abiding by regulations. 18 October 2017
Teva Pharmaceutical Industries has submitted a Biologics License Application (BLA) to the US Food and Drug Administration for fremanezumab, an anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibody for the preventive treatment of migraine. 17 October 2017
Attempts to reassure investors by the chief executive of AcelRx Pharmaceuticals could not stop the share price of the USA-based specialty pharma company from falling off a cliff on Thursday. 13 October 2017
US pharma giant Pfizer received good news today, when the US Food and Drug Administration granted approval for a new formulation of its top-selling drug Lyrica (pregabalin), which in December next year is facing patent expiry. 12 October 2017
Shares of specialty pharma firm BioDelivery Sciences International were up mid-morning, after it announced that it has entered into a Settlement Agreement over its opioid dependence treatment. 12 October 2017
The global Alzheimer’s disease (AD) market, worth $2.9 billion in 2016, is set to reach $14.8 billion by 2026, rising at a compound annual growth rate (CAGR) of 17.5%, across the 7 seven main markets (7MM: USA, Japan, France, Germany, Italy, Spain, and UK.). 10 October 2017
Eliciting comment last week was news that a US judge had reversed an earlier ban on the marketing of cholesterol treatment Praluent in a long-running court battle between Amgen and the drug’s makers – Regeneron and Sanofi and ordering a re-trial. Also attracting attention was mid-stage data on Capricor Therapeutics’ Duchenne muscular dystrophy agent CAP-1002; strong Phase III results with Zogenix’ rare epilepsy drug candidate ZX008; and positive results for Ablynx’ rare blood disorder candidate caplacizumab. 8 October 2017
Eisai’s US subsidiary has signed an exclusive licensing agreement with Uruguay-headquartered Grupo Biotoscana for Eisai's oncology and neurology products in Latin America. 5 October 2017
Two companies have been granted approval for the copycat versions of the Teva Pharmaceutical Industries (NYSE: TEVA) multiple sclerosis drug Copaxone (glatiramer acetate) 40mg/mL in Europe. 5 October 2017
Market activity on Wednesday underlined the importance of a US Food and Drug Administration (FDA) approval of a generic drug from Mylan. 4 October 2017
company Merck says it plans to invest 35 million euros ($41.1 million) in a new production line for the aseptic filling of biotech medicines under isolator at its manufacturing site of Bari, Italy. 4 October 2017
Dr Nicola Davies explores pharmaceutical development in mental health, with a focus on factors that influence the road to pharma-psych innovation. 3 October 2017
Biohaven Pharmaceutical today reported disappointing top-line results from its Phase II/III clinical trial evaluating trigriluzole compared to placebo for the treatment of patients with spinocerebellar ataxia (SCA). 2 October 2017
US CNS focused biotech firm Zogenix (Nasdaq: ZGNX) saw its shares almost triple in value on Friday after the company said that a late-stage trial of a treatment for a rare type of epilepsy met its main goal. 2 October 2017
Last week saw AbbVie entering a patent settlement with Amgen relating to the latter’s biosimilar version of blockbuster drug Humira. US Food and Drug Administration acceptance for review of Eisai’s cancer drug Lenvima in a new indication, and FDA approval for Eli Lilly’s new breast cancer drug Verzenio also figured in the news. Also attracting attention was news on the failure of Axovant Sciences’ Alzheimer’s disease candidate intepirdine. 1 October 2017
Science writer David Levine provides the latest quarterly Special Report piece, looking at the drug prices in one therapy area that are getting on people's nerves so much that they might prompt drastic action from the White House to bring down the cost of medicines across the board. 29 September 2017
Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Neimann-Pick disease, type C (NPC). 20 September 2024
US neuroscience company BioXcel Therapeutics has announced a new clinical prioritization and an update on its late-stage development programs for the treatment of agitation with BXCL501. 20 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Mid-Atlantic BioTherapeutics (MABT) has announced a collaboration with Accelero Biostructures to identify novel inhibitors of USP30, a protein linked to neurological disorders and other conditions. 5 September 2024
Praxis Precision Medicines shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. 4 September 2024